文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA放射性引导手术后生化复发患者的失败模式分析

Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
PubMed 文献 · J Nucl Med · 2025-01-03

该回顾性分析纳入100例既往接受PET引导下PSMA靶向放射性引导手术(RGS)后生化复发的前列腺癌患者,复发时行PSMA配体PET(中位PSA 0.9 ng/mL,范围0.2-14.2 ng/mL)。91例(91%)PET阳性,其中53%(48/91)仅表现为局部复发或盆腔淋巴结转移,提示PSMA配体PET可定位复发灶并为二次局部治疗提供依据。

要点

  • PSMA RGS后生化复发患者中,PSMA配体PET总检出率为91%(91/100)。
  • PSMA PET检出率随PSA升高而升高:PSA 0.2-0.49、0.5-0.99、1-1.99、≥2 ng/mL组分别为82.6%、92.6%、91.3%、96.3%。
  • 91例PET阳性患者中53%(48/91)仅为局部复发或盆腔淋巴结转移,22%(20/91)为盆腔外淋巴结转移,16%(15/91)为骨转移,9%(8/91)为内脏转移。

核心结论

  • PSMA配体PET是检测和定位PSMA RGS后生化失败患者复发病灶的有效方法,超过半数患者表现为局部区域复发,为二次局部治疗(如放疗或再次手术)提供了可能。

研究设计与样本

  • 回顾性分析纳入100例既往接受PET引导下PSMA靶向放射性引导手术(RGS)后生化复发的前列腺癌患者,复发时行PSMA配体PET(中位PSA 0.9 ng/mL,范围0.2-14.2 ng/mL)。

主要发现

  • PSMA RGS至复发PSMA配体PET的中位时间为11.4个月(范围5.5-25.6个月)。
  • 100例患者中91例(91%)PSMA配体PET阳性。
  • PSMA PET检出率在PSA 0.2-0.49、0.5-0.99、1-1.99、≥2 ng/mL组分别为82.6%、92.6%、91.3%、96.3%。
  • 91例PET阳性患者中,53%(48/91)仅为局部复发或盆腔淋巴结转移,22%(20/91)为盆腔外淋巴结转移,16%(15/91)为骨转移,9%(8/91)为内脏转移。
  • 随着国际泌尿病理学会(ISUP)分级分组升高,骨和内脏转移患者比例增加,而仅局部区域病变患者数量减少。

关键数值与推荐

  • 所有可疑复发病灶按分子影像TNM分类系统分组,检出率和病灶定位按PSA值和ISUP分级分组进行分层分析。

临床怎么用

  • 原文结论指出PSMA配体PET可用于检测和定位PSMA RGS后生化失败患者的复发病灶,超过半数患者为局部区域复发,为二次局部治疗(如放疗或再次手术)提供了可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (RGS) is evolving as a new treatment modality for patients with early biochemical recurrence of prostate cancer and disease limited to locoregional lymph nodes on PSMA-ligand PET/CT. Nevertheless, the pattern of failure (locoregional vs. systemic) after PSMA RGS remains unknown. Therefore, the aim of this retrospective analysis was to evaluate the pattern of disease using PSMA-ligand PET in patients experiencing relapse after PSMA RGS. Methods: We evaluated 100 patients with biochemical recurrence after previous PET-guided PSMA RGS who underwent PSMA-ligand PET (median prostate-specific antigen [PSA], 0.9 ng/mL; range, 0.2-14.2 ng/mL). All suspicious lesions for recurrent prostate cancer were grouped according to the molecular imaging TNM classification system. Detection rates and lesion localization were determined and stratified by PSA values and the International Society of Urological Pathology grade group. Further, lesion localization was compared before and after PSMA RGS. Results: The median time between PSMA RGS and PSMA-ligand PET for relapse was 11.4 mo (range, 5.5-25.6 mo). In total, 91 of 100 (91%) patients showed PSMA-ligand-positive findings. PSMA PET detection rates were 82.6%, 92.6%, 91.3%, and 96.3% for PSA levels of 0.2-0.49, 0.5-0.99, 1-1.99, and at least 2 ng/mL, respectively. More than half of the patients (53%; 48/91) showed local recurrence or pelvic lymph node metastases only. Extrapelvic lymph node metastases, bone metastases, and visceral metastases were present in 22% (20/91), 16% (15/91), and 9% (8/91) of the patients, respectively. With increasing International Society of Urological Pathology grade group, the percentage of patients with bone and visceral metastases increased, whereas the number of patients with only locoregional disease decreased. Conclusion: PSMA-ligand PET is a useful method to detect and localize recurrent disease in patients with biochemical failure after PSMA RGS, with more than half of the patients presenting with locoregional recurrence, offering the potential for a second local therapy (e.g., radiation therapy or repeated surgery).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schweiger L, Maurer T, Simon R, et al. Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery. J Nucl Med. 2025. PMID: 39327015. doi:10.2967/jnumed.124.268151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。